Ask AI
ProCE Banner Activity

Harnessing TROP-2 and TIGIT: Emerging Strategies to Enhance Outcomes in Lung Cancer Care 

Clinical Thought

This expert commentary explores the clinical potential of therapies targeting TROP-2 and TIGIT in lung cancer, highlighting key data from recent clinical trials, practical insights on toxicity management, and emerging opportunities in the treatment of both NSCLC and SCLC. 

Released: July 11, 2025

Expiration: January 10, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Disclosure

Primary Author

Lyudmila Bazhenova, MD: consultant/advisor/speaker: AbbVie, Anheart, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Gilead, Johnson & Johnson, Merck, Natera, Novocure, Pfizer, Regeneron, Revolution Medicine, Sanofi, Summit, Teligene.

Jyoti D. Patel, MD, FASCO: consultant/advisor/speaker: AbbVie, AstraZeneca, Gilead, Takeda.